We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Solid Global Prospects Drive Align's (ALGN) Q2 Earnings?
Read MoreHide Full Article
Align Technology, Inc.’s (ALGN - Free Report) solid Invisalign Technology prospects and growth in North America and internationally, particularly in the Asia-Pacific and EMEA regions, raise optimism. The continued strong uptake of iTero scanners across all geographies is impressive.
We expect this geographical strength to get reflected in second-quarter 2018 results, which are scheduled for release on Jul 25, after market close.
Click here to know how the company’s overall Q2 performance is expected to be.
Solid Global Prospects
Align Technology‘s strategy of international expansion got a solid impetus with the achievement of a landmark in Invisalign adoption. The company recently announced the completion of one million shipments in the EMEA region.
Of late, the company’s international Invisalign volumes have been strong with 43.4% growth registered in the first quarter of 2018 on continued adoption in EMEA and APAC regions.
In EMEA, first-quarter volumes were up 36.6% on solid Invisalign adoption in the markets of Iberia and France as well as rapid growth in smaller markets like Eastern Europe and Central Europe along with Benelux. In the Asia-Pacific region, the company witnessed a 56.1% surge in first-quarter volumes, led by China, Japan and Australia.
While China stood close as the second largest market after the United States for Align Technology, Iberia was a close third.
The international teen case grew 60% year over year in the last reported quarter. Notably, it was the sixth consecutive quarter when Invisalign teenage patient base grew faster than the adult patient’s customer base.
We expect to see a similar trend in the yet-to-be-reported quarter result as well.
The company had introduced a clear Aligner solution for teen Class II correction — the InvisAlign Technology Teen with mandibular advancement — in certain markets of Canada, EMEA and APAC in 2017.
These developments are indicative of the growing popularity of Align Technology’s dental products in the international market.
Zacks Rank & Other Stocks to Consider
Align Technology carries a Zacks Rank #1 (Strong Buy).
Other top-ranked stocks in the broader medical space are Genomic Health , Abbott (ABT - Free Report) and Baxter International Inc. (BAX - Free Report) .
Abbott has a projected long-term earnings growth rate of 12% and a Zacks Rank of 2 (Buy).
Baxter has a projected long-term earnings growth rate of 13.4%. The stock carries a Zacks Rank of 2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Can Solid Global Prospects Drive Align's (ALGN) Q2 Earnings?
Align Technology, Inc.’s (ALGN - Free Report) solid Invisalign Technology prospects and growth in North America and internationally, particularly in the Asia-Pacific and EMEA regions, raise optimism. The continued strong uptake of iTero scanners across all geographies is impressive.
We expect this geographical strength to get reflected in second-quarter 2018 results, which are scheduled for release on Jul 25, after market close.
Click here to know how the company’s overall Q2 performance is expected to be.
Solid Global Prospects
Align Technology‘s strategy of international expansion got a solid impetus with the achievement of a landmark in Invisalign adoption. The company recently announced the completion of one million shipments in the EMEA region.
Of late, the company’s international Invisalign volumes have been strong with 43.4% growth registered in the first quarter of 2018 on continued adoption in EMEA and APAC regions.
Align Technology, Inc. Price and EPS Surprise
Align Technology, Inc. Price and EPS Surprise | Align Technology, Inc. Quote
In EMEA, first-quarter volumes were up 36.6% on solid Invisalign adoption in the markets of Iberia and France as well as rapid growth in smaller markets like Eastern Europe and Central Europe along with Benelux. In the Asia-Pacific region, the company witnessed a 56.1% surge in first-quarter volumes, led by China, Japan and Australia.
While China stood close as the second largest market after the United States for Align Technology, Iberia was a close third.
The international teen case grew 60% year over year in the last reported quarter. Notably, it was the sixth consecutive quarter when Invisalign teenage patient base grew faster than the adult patient’s customer base.
We expect to see a similar trend in the yet-to-be-reported quarter result as well.
The company had introduced a clear Aligner solution for teen Class II correction — the InvisAlign Technology Teen with mandibular advancement — in certain markets of Canada, EMEA and APAC in 2017.
These developments are indicative of the growing popularity of Align Technology’s dental products in the international market.
Zacks Rank & Other Stocks to Consider
Align Technology carries a Zacks Rank #1 (Strong Buy).
Other top-ranked stocks in the broader medical space are Genomic Health , Abbott (ABT - Free Report) and Baxter International Inc. (BAX - Free Report) .
Genomic Health has an expected earnings growth rate of 187.5% for the current quarter. The stock sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Abbott has a projected long-term earnings growth rate of 12% and a Zacks Rank of 2 (Buy).
Baxter has a projected long-term earnings growth rate of 13.4%. The stock carries a Zacks Rank of 2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>